Click a keyword to view all the abstracts on this site tagged with that keyword.
- Anakinra
- anakinra and bone disease
- Anakinra and cardiovascular disease
- anakinra and familial Mediterranean fever
- anakinra and fever
- Anakinra and gout
- anakinra and treatment
- analgesics
- Anatomy
- Anatomy and education
- Anatomy and educational innovation
- ANCA
- ANCA and body mass
- ANCA and cardiovascular disease
- ANCA and Churg-Strauss syndrome
- ANCA and Elderly
- ANCA and systemic lupus erythematosus (SLE)
- ANCA and vasculitis
- ANCA and Wegener's granulomatosis
- and SLE
- Anemia
- Anemia and gout
- anemia and systemic lupus erythematosus (SLE)
- angiitis
- angioedema and pediatric rheumatology
- Angiogenesis
- angiogenesis and autoimmune diseases
- Angiogenesis and endothelial cells
- Angiogenesis and inflammatory arthritis
- angiogenesis and pregnancy
- angiogenesis and psoriasis
- Angiogenesis and rheumatoid arthritis
- Angiogenesis and rheumatoid arthritis (RA)
- Angiogenesis and signal transduction
- Angiogenesis and systemic sclerosis
- Angiography
- angiopoietin
- angiopoietin and inflammatory arthritis
- angiopoietin and vasculitis
- Angiotensin
- Angiotensin and rheumatoid arthritis
- Animal models
- animal models and apoptosis
- Animal models and arthritis
- animal models and autoimmune diseases
- animal models and catecholamines
- animal models and glomerulonephritis
- Animal models and inflammation
- animal models and inflammatory arthritis
- animal models and lupus nephritis
- Animal models and lymph node
- Animal models and matrix metalloproteinase (MMP)
- Animal models and metabolic syndrome
- Animal models and mycophenolate mofetil
- animal models and non-human primates (NHPs)
- Animal models and osteoarthritis
- Animal models and osteoclastogenesis
- animal models and pain
- animal models and rheumatoid arthritis
- animal models and rheumatoid arthritis (RA)
- animal models and risk
- Animal models and scleroderma
- animal models and signal transduction
- animal models and small molecules
- animal models and spondylarthritis
- animal models and steroids
- animal models and synovial cells
- animal models and synovium
- animal models and systemic lupus erythematosus (SLE)
- Animal models and systemic sclerosis
- animal models and therapeutic targeting
- animal models and therapy
- animal models and tofacitinib
- animal models and tolerance
- animal models and toll-like receptors
- animal models and transcription factor
- animal models and transcriptional regulation
- animal models and treatment
- animal models and tumor necrosis factor (TNF)
- animal models and type II collagen
- animal models and ultrasound
- animal models and vaccines
- animal models and viruses
- Ankle
- ankle and rheumatoid arthritis (RA)
- Ankylosing spondylitis (AS)
- Ankylosing spondylitis (AS) and anti-TNF therapy
- ankylosing spondylitis (AS) and axial spondyloarthritis
- Ankylosing spondylitis (AS) and biomarkers
- ankylosing spondylitis (AS) and bone density
- Ankylosing spondylitis (AS) and cardiovascular disease
- ankylosing spondylitis (AS) and cartilage
- Ankylosing spondylitis (AS) and chronic disease care
- Ankylosing spondylitis (AS) and clinical practice
- ankylosing spondylitis (AS) and clinical trials
- ankylosing spondylitis (AS) and comparative effectiveness and harms
- Ankylosing spondylitis (AS) and computed tomography (CT)
- ankylosing spondylitis (AS) and death
- ankylosing spondylitis (AS) and diagnosis
- ankylosing spondylitis (AS) and enthesis
- Ankylosing spondylitis (AS) and epidemiologic methods
- Ankylosing spondylitis (AS) and epigenetics
- Ankylosing spondylitis (AS) and exercise
- Ankylosing spondylitis (AS) and extraarticular manifestations
- Ankylosing spondylitis (AS) and familial Mediterranean fever
- ankylosing spondylitis (AS) and fibromyalgia
- Ankylosing spondylitis (AS) and functional status
- Ankylosing spondylitis (AS) and genetic disorders
- Ankylosing spondylitis (AS) and genetics
- Ankylosing spondylitis (AS) and genomics
- Ankylosing spondylitis (AS) and glucocorticoids
- Ankylosing spondylitis (AS) and guidelines
- Ankylosing spondylitis (AS) and hip disorders
- ankylosing spondylitis (AS) and human leukocyte antigens (HLA)
- Ankylosing spondylitis (AS) and infection
- ankylosing spondylitis (AS) and inflammation
- ankylosing spondylitis (AS) and inflammatory arthritis
- Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD)
- Ankylosing spondylitis (AS) and infliximab
- ankylosing spondylitis (AS) and laboratory tests
- ankylosing spondylitis (AS) and longitudinal studies
- Ankylosing spondylitis (AS) and macrophage migration inhibitory factor (MIF)
- Ankylosing spondylitis (AS) and magnetic resonance imaging (MRI)
- Ankylosing spondylitis (AS) and major histocompatibility complex (MHC)
- ankylosing spondylitis (AS) and medication
- Ankylosing spondylitis (AS) and microbiome
- ankylosing spondylitis (AS) and mucosal T cells
- Ankylosing spondylitis (AS) and nonsteroidal antiinflammatory drugs (NSAIDs)
- Ankylosing spondylitis (AS) and osteoporosis
- Ankylosing spondylitis (AS) and outcome measures
- ankylosing spondylitis (AS) and patient questionnaires
- ankylosing spondylitis (AS) and physical activity
- Ankylosing spondylitis (AS) and polymorphism
- ankylosing spondylitis (AS) and posture
- ankylosing spondylitis (AS) and prognostic factors
- Ankylosing spondylitis (AS) and proteomics
- ankylosing spondylitis (AS) and psoriatic arthritis
- Ankylosing spondylitis (AS) and quality of care
- Ankylosing spondylitis (AS) and quality of life
- Ankylosing spondylitis (AS) and radiography
- Ankylosing spondylitis (AS) and range of motion
- ankylosing spondylitis (AS) and registries
- ankylosing spondylitis (AS) and registry
- ankylosing spondylitis (AS) and regulatory cells
- Ankylosing spondylitis (AS) and rheumatoid arthritis (RA)
- Ankylosing spondylitis (AS) and sarcopenia
- Ankylosing spondylitis (AS) and self-management
- ankylosing spondylitis (AS) and sleep disorders
- ankylosing spondylitis (AS) and socioeconomic status
- ankylosing spondylitis (AS) and spine involvement
- Ankylosing spondylitis (AS) and spondylarthritis
- Ankylosing spondylitis (AS) and spondylarthropathy
- Ankylosing spondylitis (AS) and thrombosis
- ankylosing spondylitis (AS) and treatment
- Ankylosing spondylitis (AS) and tumor necrosis factor (TNF)
- ankylosing spondylitis (AS) and ultrasound
- Ankylosing spondylitis (AS) and uveitis
- ankylosing spondylitis (AS) and well-being
- Ankylosing spondylitis (AS) and work
- Annexins
- Anti TNF
- anti-beta2 Glycoprotein I antibodies
- anti-CCP antibodies
- anti-CCP antibodies and anti-citrullinated protein/peptide antibodies (ACPA)
- anti-CCP antibodies and anti-mutated citrullinated vimentin
- anti-CCP antibodies and biomarkers
- anti-CCP antibodies and disease-modifying antirheumatic drugs
- anti-CCP antibodies and inflammatory arthritis
- Anti-CCP antibodies and interstitial lung disease
- Anti-CCP antibodies and juvenile idiopathic arthritis (JIA)
- Anti-CCP antibodies and reactive arthritis
- anti-CCP antibodies and rheumatoid arthritis
- Anti-CCP antibodies and rheumatoid arthritis (RA)
- Anti-centromere antibodies (ACA) and systemic sclerosis
- anti-citrullinated protein/peptide antibodies (ACPA)
- anti-citrullinated protein/peptide antibodies (ACPA) and arthritis
- anti-citrullinated protein/peptide antibodies (ACPA) and autoimmune diseases
- anti-citrullinated protein/peptide antibodies (ACPA) and lupus nephritis
- anti-citrullinated protein/peptide antibodies (ACPA) and methotrexate (MTX)
- Anti-citrullinated protein/peptide antibodies (ACPA) and rheumatoid arthritis (RA)
- anti-citrullinated protein/peptide antibodies (ACPA) and therapeutic targeting
- Anti-depressant
- Anti-DNA
- anti-DNA and antibodies
- anti-dsDNA
- anti-dsDNA and glomerulonephritis
- anti-dsDNA and immunoglobulin (IG)
- anti-dsDNA and nephritis
- anti-mutated citrullinated vimentin
- Anti-resorptives
- anti-TNF therapy
- anti-TNF therapy and arthritis
- anti-TNF therapy and axial spondyloarthritis
- anti-TNF therapy and biomarkers
- anti-TNF therapy and bone metabolism
- Anti-TNF therapy and cancer
- Anti-TNF therapy and certolizumab pegol
- anti-TNF therapy and cytokines
- anti-TNF therapy and extraarticular manifestations
- anti-TNF therapy and eye disease